2 edition of Cardiovascular diabetology found in the catalog.
Includes bibliographical references and index.
|The Physical Object|
|Pagination||xvi, 125 p. :|
|Number of Pages||92|
|2||Advances in cardiology -- v. 45|
|Hyperglycemia and the pathobiology of diabetic complications / Aronson, D. Endothelial dysfunction in normal and abnormal glucose metabolism / Esper, R.J. ... [et al.] Biomarkers in cardiovascular diabetology: interleukins and matrixins / Fisman, E.Z. ; Adler, Y.; Tenenbaum, A. Arterial elasticity in cardiovascular disease: focus on hypertension, metabolic syndrome and diabetes / Cernes, R.; Zimlichman, R.; Shargorodsky, M. Hypertension and diabetes / Grossman, E.; Messerli, F.H. Impaired glucose metabolism and cerebrovascular diseases / Tanne, D. Impact of metabolic syndrome in patients with acute coronary syndrome / Feinberg, M.S.; Schwartz, R.; Behar, S. Optimal management of combined dyslipidemia: what have we behind statins monotherapy? / Tenenbaum, A. ... [et al.] Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects / Fisman, E.Z.; Motro, M.; Tenenbaum, A.|
nodata File Size: 4MB.
Got Parts? An Insiders Guide to Managing Life Successfully with Dissociative Identity Disorder (New Horizons in Therapy)
Four phase III studies evaluated the efficacy and safety of the naltrexone-bupropion combination versus placebo, for 56 weeks. In the SCALE Obesity and Pre diabetes study, a 56-week, randomized, double-blind, placebo-controlled clinical trial  in 3731 people with overweight or obesity without type 2 diabetes, patients treated with liraglutide lost a mean of 8.
The present review focuses on the impact of risk factors in the global cardiovascular risk, and the role of detecting subclinical atherosclerosis and silent ischemia in the asymptomatic patient with diabetes. The major adverse effects with orlistat reported in all studies are gastrointestinal. Cardiovascular diabetology
In another study , a 24-week prospective, randomized, single blind study between orlistat 120 mg three times a day and placebo in 80 adult people with obesity, orlistat has shown a reduction in weight 4. Even though the development of obesity is multifactorial with genetic, environmental and lifestyle causes, it is extensively associated with comorbidities such as cardiovascular diseases, diabetes, hypertension, cancer, and sleep disorders [,,].
The BLOOM trial Behavioral Modification and Lorcaserin for Overweight and Obesity Managementa double blinded, randomized, placebo-controlled study in 3182 adults with obesity or overweight evaluated weight loss in patients treated with lorcaserin HCl 10 mg twice daily bid or placebo for 2 years. Diabetes also increases coronary death rates conferring the patient a worst prognosis after having the first CHD event . Cardiovascular diabetology Not every article in a journal is considered primary research and therefore "citable", this chart shows the ratio of a journal's articles including substantial research research articles, conference papers and reviews in three year windows vs.
CMIT is a surrogate marker for new acute myocardial infarction and stroke in Cardiovascular diabetology above 65 years old , when maximal IMT is above 1.
These exceptional editors performed in the top percentile of journals based on data collected from the Journal Author Satisfaction Survey.
Increased CIMT above 1 mm is also predictive for CHD in younger individuals without previous cardiovascular events .
Cardiovascular Diabetology is the world's foremost journal specifically devoted to this issue.